Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
about
Molecular analysis of a mutated FSH receptor detected in a patient with spontaneous ovarian hyperstimulation syndromeOvarian hyperstimulation syndrome: pathophysiology, staging, prediction and preventionPrevention of Ovarian Hyperstimulation Syndrome: A ReviewGnRH agonist for triggering of final oocyte maturation: time for a change of practice?Individual luteolysis pattern after GnRH-agonist trigger for final oocyte maturation.Kinase insert domain receptor/vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndromeGnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles-A Systematic PRISMA Review and Meta-analysisZinc finger gene 217 (ZNF217) Promoted Ovarian Hyperstimulation Syndrome (OHSS) through Regulating E2 Synthesis and Inhibiting Thrombospondin-1 (TSP-1).Ovarian hyperstimulation syndrome: current views on pathophysiology, risk factors, prevention, and management.Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocolTriggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma.A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndromeNew algorithm for OHSS preventionOvarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles.Hematocrit as a simple method to predict and manage ovarian hyperstimulation syndrome in assisted reproduction.Is the GnRH Antagonist Protocol Effective at Preventing OHSS for Potentially High Responders Undergoing IVF/ICSI?Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and "freeze-all": in-depth analysis of genetic predisposition.Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist ProtocolEfficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy.Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment.Prediction of ovarian hyperstimulation syndrome in coasted patients in an IVF/ICSI program.Optimum oocyte retrieved and transfer strategy in young women with normal ovarian reserve undergoing a long treatment protocol: a retrospective cohort studyPredictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles.Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxisRandomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART)Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: "tap early and often" versus hospitalization.Reproductive outcome is optimized by genomic embryo screening, vitrification, and subsequent transfer into a prepared synchronous endometrium.GnRH analogues in the prevention of ovarian hyperstimulation syndromeCombination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective studyGnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main StudyAre pregnancy rates compromised following embryo freezing to prevent OHSS?Follicle curetting at the time of oocyte retrieval increases the oocyte yield.Corifollitropin stimulation in combination with GnRH-antagonists after estradiol valerate pre-treatment. A pilot study on patientfriendly IVF.Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial.Nephrotic sydrome developing in severe ovarian hyperstimulation syndromeGnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.
P2860
Q24337136-2F0B6F3D-F467-43A3-BA1C-E305313193E3Q26827593-9C17CC67-59FE-4C2F-A1F6-4BBAB737FF22Q26828442-6C368957-9E9B-4171-B156-11CCAD851E11Q28308094-76107D22-6C4D-46BC-8315-67776538CADCQ33620822-CCAB1D95-8091-4D28-947B-3899232E3701Q33624231-B8037F8D-9072-4BE5-869D-8125E3843C09Q33770533-B59E6238-A809-4F2A-A256-3C50DC75744AQ33789896-9F81A011-2DA1-4A29-B4F6-691242733FEEQ33844520-9FEF005A-0F9E-4B2D-A322-7B8DBCD85103Q33888265-FFF2FDF7-A40E-4119-876D-F58E3B8A3F89Q33897147-B1C2D242-B24D-4A76-8802-744F7AF02256Q34249374-EC9A5A74-1E31-4EF2-880B-28B8842E00D6Q34997672-ED939E90-B50E-4C22-B977-DE239904638AQ35071420-37A17523-A4EB-4469-BE22-FF14BCFDB083Q35591046-550B2636-1092-487D-BB65-CD4310354D8AQ35769428-A4F186F7-31EE-4ED8-9CE8-792CD62F9417Q35770019-4CC6DBFA-21C0-4601-A5A9-51C6DD9D8285Q35808082-15ED216B-2A91-4BBA-8418-0007A6FF3C95Q35938164-CFDDF184-5EBE-478D-BA49-671455C2C1EBQ35947620-5406EC13-3488-4A9C-B5FF-7846A13AF7C2Q36060453-88A931B0-A23A-4477-AC6A-3932990B0717Q36085346-E473CF87-F4D4-478C-8BB9-83737B4887C0Q36112513-160A19DE-07F5-46B4-9615-78513322DE19Q36133371-8DC3C467-2889-4173-9C20-B5E6AA3CB458Q36192133-D935EEF1-B153-48F1-8628-0DC60BBE8B7DQ36234933-C80DEC9E-1336-47BB-BCC8-274291C0AB0EQ36406595-241084E0-10F7-4DFC-B32E-C845B90C88D9Q36433446-27FB164D-5DD8-4461-9E50-5AF8DC1123A1Q36620273-AD2A86AD-48E8-4AE9-9D3A-7617CC39DAF0Q36670059-3BD852C6-29E9-4EFA-91CA-A5551CAC13FDQ36957480-8A9BC257-446B-4BD4-9748-B75AFBBF2C45Q36966423-E6D6E291-6807-4BDA-9A19-C88FE76BB9E4Q36970343-83E225A1-0EA9-403D-8BAE-6F13A66AB94BQ36994477-4E59A89F-7A77-4348-83AE-C6EA1C539FB0Q37017881-746A6DCB-77E5-49E7-B5CA-FB0282EFBB45Q37313066-833DA262-CD39-4B30-BBED-C0FB5DF8C86BQ37326952-4B49F9A2-CD64-40BB-AA44-BFDCCF877DB5Q37350477-66BFD270-F16C-4178-A3CD-683A55E5E2D5Q37512465-A6CA70CE-84A4-41E3-A10B-2105A3397668Q37598922-6AB1CD07-BA63-4881-92A4-2ACD7A35F632
P2860
Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Incidence and prediction of ov ...... in vitro fertilization cycles.
@en
Incidence and prediction of ov ...... in vitro fertilization cycles.
@nl
type
label
Incidence and prediction of ov ...... in vitro fertilization cycles.
@en
Incidence and prediction of ov ...... in vitro fertilization cycles.
@nl
prefLabel
Incidence and prediction of ov ...... in vitro fertilization cycles.
@en
Incidence and prediction of ov ...... in vitro fertilization cycles.
@nl
P2093
P50
P1476
Incidence and prediction of ov ...... in vitro fertilization cycles.
@en
P2093
Cristina Pozzobon
Efstratios M Kolibianakis
Evangelos G Papanikolaou
Human M Fatemi
Michel Camus
P304
P356
10.1016/J.FERTNSTERT.2005.07.1292
P407
P577
2006-01-01T00:00:00Z